Subject: Global Update: AIDS Divisions of 2 Large Drug Makers Form Company to Focus on the Disease

Global Update: AIDS Divisions of 2 Large Drug Makers Form Company to Focus on the Disease

The New York Times - November 10, 2009
Donald G. Mcneil Jr.

http://www.aegis.org/news/nyt/2009/NYT091108.html

Two of the world's biggest drug makers last week spun off their divisions that manufacture AIDS drugs and combined them into one company focusing on the disease.

The new company, ViiV Healthcare, will initially be 85 percent controlled by GlaxoSmithKline and 15 percent controlled by Pfizer. With headquarters in London, the company initially has a portfolio of 10 licensed drugs, including some of the earliest, like AZT and lamivudine, and later ones, like maraviroc, with combined sales of about $2.7 billion in 2008. It also has seven drugs in the pipeline.

The companies say they will try to develop new drugs and new formulations of existing ones, like combination doses for children. ViiV Healthcare will also seek partnerships with other companies to develop multidrug cocktails.

Some in the field were pleased. Dr. Jorge Bermudez, executive secretary of Unitaid, an agency based in Geneva that buys AIDS drugs for the poor, quickly invited ViiV to join its "patent pool" holding licenses on medicines so they can be made generically.

But Mark Harrington, executive director of the Treatment Action Group and a longtime AIDS activist, was skeptical. Mr. Harrington said he worried that separating AIDS work from the larger companies could result, for example, in too little money for a big clinical trial. And the mergers of the last decade meant fewer scientists assigned to AIDS research.

"We'd love to be proved wrong," he said, "but we're worried that fewer companies in the field could mean innovation is slowed down." 

091110
NYT091108

Copyright ? 2009 - The New York Times Company. All Rights Reserved. All New York Times articles contained on the AEGiS web site are protected by United States copyright law and may not be reproduced, distributed, transmitted, displayed, published or broadcast without the prior written permission of The New York Times Company. You may not alter or remove any trademark, copyright or other notice from copies of the content. However, you may download articles (one machine readable copy and one print copy per page) for your personal, noncommercial use only.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from the Elton John AIDS Foundation, National Library of Medicine, AIDS Walk of Orange County, and donations from users like you.

Always watch for outdated information. This article first appeared in 2009. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ?1980, 2009. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.